Franklin Resources Inc. purchased a new stake in shares of HilleVax, Inc. (NASDAQ:HLVX – Get Rating) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 672,512 shares of the company's stock, valued at approximately $7,351,000. Franklin Resources Inc. owned approximately 2.01% of HilleVax as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Strs Ohio bought a new stake in HilleVax in the 2nd quarter worth approximately $32,000. TD Asset Management Inc. bought a new stake in HilleVax in the 2nd quarter worth approximately $203,000. Frazier Life Sciences Management L.P. bought a new stake in HilleVax in the 2nd quarter worth approximately $101,493,000. JPMorgan Chase & Co. bought a new stake in HilleVax in the 2nd quarter worth approximately $76,000. Finally, Alps Advisors Inc. bought a new stake in HilleVax in the 2nd quarter worth approximately $217,000.
Get HilleVax alerts:HilleVax Trading Up 4.9 %
NASDAQ:HLVX opened at $20.00 on Thursday. The company has a quick ratio of 34.77, a current ratio of 34.77 and a debt-to-equity ratio of 0.02. HilleVax, Inc. has a 12 month low of $7.90 and a 12 month high of $24.42. The company has a 50 day simple moving average of $19.30 and a two-hundred day simple moving average of $14.99.
HilleVax (NASDAQ:HLVX – Get Rating) last posted its earnings results on Thursday, November 10th. The company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.88) by $0.43. Sell-side analysts expect that HilleVax, Inc. will post -6.93 earnings per share for the current fiscal year.HilleVax Company Profile
(Get Rating)
HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Further Reading
- Get a free copy of the StockNews.com research report on HilleVax (HLVX)
- Will Easing Of Covid Rules Slash Risk For Chinese EV Maker NIO?
- Santa Claus Rally? Here's What Needs to Happen
- Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
- Dark Clouds Are Gathering For Cloud Stocks
- 3 Dividend Growers With Good 2023 Growth Prospects
Want to see what other hedge funds are holding HLVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HilleVax, Inc. (NASDAQ:HLVX – Get Rating).
Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.